Why Cooper Companies’ sustainability report is drawing investor attention
Cooper Companies (COO) is back in focus after releasing its 2025 Corporate Sustainability Report, which introduces first-time Scope 3 emissions disclosure, alignment with SASB and TCFD frameworks, and updates on vision care and women’s health products.
See our latest analysis for Cooper Companies.
Cooper Companies’ recent 19.64% 1 month share price return and 3.13% 1 day move suggest improving momentum after a year to date share price decline of 8.52% and a 3 year total shareholder return that is down 21.55%.
If this sustainability driven move has you thinking about other potential opportunities in healthcare and AI, it could be a good moment to scan 40 healthcare AI stocks
With Cooper Companies trading at $74.20, showing an intrinsic value estimate at a 46% discount and an 8.6% gap to the average analyst target, investors have to ask: is there real upside here or is the market already baking in future growth?
Most Popular Narrative: 7.9% Undervalued
On the most followed narrative, Cooper Companies’ fair value of $80.57 sits above the recent $74.20 close, framing an underpriced story built on earnings and cash flow potential rather than current margins.
Free cash flow is poised to inflect higher as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity, with management guiding for approximately $2 billion in free cash flow over the next three years. This improved cash generation, tied to strong cost discipline and revenue momentum, will further benefit shareholders via debt reduction and share repurchases.
Want to see how this outlook turns today’s modest profitability into a higher fair value? The narrative leans on faster earnings growth, fatter margins, and a future earnings multiple that assumes the market will pay up for that shift. The exact mix of growth, margins, and valuation is where the story gets interesting.
Result: Fair Value of $80.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Cooper Companies narrative still hinges on MyDAY converting trial activity into sustained sales, and on fertility and IUD markets avoiding a prolonged slowdown.
Find out about the key risks to this Cooper Companies narrative.
Another View on Cooper Companies’ valuation
There is a twist when you look at Cooper Companies through earnings multiples. The stock trades on a P/E of 61.4x, which is far above the US Medical Equipment industry at 26.5x, the peer average at 24.1x, and the 35.8x fair ratio that our model suggests the market could move toward over time. That gap points to potential valuation risk if sentiment cools. How comfortable are you with paying such a premium for this story?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
This mix of optimism and concern around Cooper Companies can feel conflicting, so it makes sense to review the full picture quickly and decide where you stand by weighing 2 key rewards and 1 important warning sign
Looking for more ideas beyond Cooper Companies?
If Cooper Companies has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not late to the next move.
- Spot potential high-upside trades early by scanning 20 elite penny stocks with strong financials while prices are still low enough to move the needle on your portfolio.
- Strengthen your core holdings by checking the solid balance sheet and fundamentals stocks screener (47 results) and focus on companies with financial foundations that can better handle tough conditions.
- Get ahead of the crowd by reviewing the screener containing 18 high quality undiscovered gems before more investors start paying attention and reprice those opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com